Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022116 (
ischemia
)
91,303
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously showed that the neuroactive steroid 3alpha-ol-5-beta-pregnan-20-one hemisuccinate (
ABHS
), a low-affinity NMDA receptor antagonist, improves behavior in rabbits following spinal cord
ischemia
. The present study assessed whether this also occurs following cerebral ischemia. We used the rabbit small clot embolic stroke model (RSCEM), a model of multiple infarct
ischemia
, which has a well-defined behavioral endpoint. Quantal analysis for each treatment determines microclots (mg) that produce neurologic dysfunction in 50% of a group of animals (P(50)), with treatment considered beneficial if it increases the P(50) compared to controls.
ABHS
(25 mg/kg) injected 5 min post-embolization significantly (P = 0.046) increased the P(50) to 2.60 +/- 0.69 mg compared to 1.15 +/- 0.19 mg in controls but was ineffective at longer intervals. For combination studies with tissue plasminogen activator (tPA), a cumulative control curve (P(50) = 1.18 +/- 0.25 mg) was used for statistical comparisons. Low-dose tPA (0.9 mg/kg) and
ABHS
, given 60 min post-embolization, improved behavior synergistically (P(50) = 2.44 +/- 0.44 mg), compared to tPA (P(50) = 1.25 +/- 0.25 mg) or
ABHS
(P(50) = 1.05 +/- 0.24 mg) alone. A standard tPA dose (3.3 mg/kg) significantly increased the P(50) at 60 (2.69 +/- 0.19 mg) but not 180 min (1.28 +/- 0.31 mg) post-embolization. However, when combined with
ABHS
, an effect was evident even 180 min post-embolization (P(50) = 2.31 +/- 0.48 mg). Although the therapeutic window for
ABHS
is limited, it significantly enhanced neuroprotection by low-dose tPA and increased the therapeutic window for tPA, suggesting that it may be most useful as a co-therapy with thrombolytics for stroke.
...
PMID:3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. 1630 Jul 57